Prognostic Value of Systemic Immune‐Inflammation Index in Patients With Gynecological Tumors: A Systematic Review and Meta‐Analysis

ABSTRACT

This meta‐analysis (MA) systematically evaluated the application value of systemic immune‐inflammation index (SII) in the prognosis of patients with gynecological tumors. Electronic databases including PubMed, Embase, Cochrane Library, Web of Science, Elsevier, and Wiley were searched for randomized controlled trials (RCTs) of SII according to inclusion and exclusion criteria, with the search period extending from the inception of the databases to November 2024. Clinical outcomes included overall survival (OS), disease‐free survival (DFS), progression‐free survival (PFS), and distant metastasis‐free survival (DMFS). The quality of the included articles was assessed adopting the Cochrane systematic review method, and MA was conducted adopting Stata 17.0 software. A total of eight studies (10 trials) were included, with high SII having an observable negative impact on OS [Tau ²  = 0.20, 95% confidence interval (CI): 1.30–2.58; Z  = 3.47, p  = 0.0005]. High SII had an observable negative impact on DFS and PFS (Tau ²  = 0.08, 95% CI: 1.25–1.97; Z  = 3.89, p  = 0.0001). High SII had an observable negative impact on DMFS (95% CI: 1.20–1.86; Z  = 3.54, p  = 0.0004). The MA results indicate that a high SII index predicts poor survival outcomes in patients with gynecological tumors and is an effective indicator for prognosis in clinical practice.